ID: ALA5171680

Max Phase: Preclinical

Molecular Formula: C32H34Cl2N4O3

Molecular Weight: 593.56

Representations

Canonical SMILES:  CC1(C)C(=O)N(c2ccc(N3CC(CN[C@H]4CC[C@@H](C(=O)O)CC4)C3)cc2)c2cc(Cl)ccc2-c2cc(Cl)cnc21

Standard InChI:  InChI=1S/C32H34Cl2N4O3/c1-32(2)29-27(13-22(34)16-36-29)26-12-5-21(33)14-28(26)38(31(32)41)25-10-8-24(9-11-25)37-17-19(18-37)15-35-23-6-3-20(4-7-23)30(39)40/h5,8-14,16,19-20,23,35H,3-4,6-7,15,17-18H2,1-2H3,(H,39,40)/t20-,23+

Standard InChI Key:  AFZLTKHKFOYSAP-UHGJSFDGSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 593.56

Molecular Weight (Monoisotopic): 592.2008

AlogP: 6.68

#Rotatable Bonds: 6

Polar Surface Area: 85.77

Molecular Species: ZWITTERION

HBA: 5

HBD: 2

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 4.43

CX Basic pKa: 10.66

CX LogP: 3.89

CX LogD: 3.89

Aromatic Rings: 3

Heavy Atoms: 41

QED Weighted: 0.33

Np Likeness Score: -0.57

References

1. Arai Y, Kiyotsuka Y, Nagamochi M, Oyama K, Izumi M..  (2022)  Lead optimization of pyrido[2,3-d][1]benzazepin-6-one derivatives leading to the discovery of a potent, selective, and orally available human parathyroid hormone receptor 1 (hPTHR1) antagonist (DS69910557).,  64  [PMID:35487102] [10.1016/j.bmc.2022.116763]

Source

Source(1):

• Scientific Literature